• Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (ATCC; Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC; Cosmic-CLP; DepMap).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC; Cosmic-CLP; DepMap).
  

PubMed=4332311; DOI=10.1002/1097-0142(197201)29:1<117::aid-cncr2820290119>3.0.CO;2-R
Rangan S.R.S.
A new human cell line (FaDu) from a hypopharyngeal carcinoma.
Cancer 29:117-121(1972)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6935474; DOI=10.1093/jnci/66.2.239
Wright W.C., Daniels W.P., Fogh J.
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
J. Natl. Cancer Inst. 66:239-247(1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=2990217
Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Am. J. Pathol. 119:361-366(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=3138611; DOI=10.1177/019459988809800603
Wustrow T.P., Raffael A., Valet G.K.
Multiparametric flow cytometry of human squamous cell carcinoma lines from the head and neck.
Otolaryngol. Head Neck Surg. 98:552-557(1988)

PubMed=1394225
Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L., Casey G.
Frequent p53 mutations in head and neck cancer.
Cancer Res. 52:5997-6000(1992)

DOI=10.1016/B978-0-12-333530-2.50007-1
Carey T.E.
Head and neck tumor cell lines.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994)

PubMed=8552396
Patel A.M., Incognito L.S., Schechter G.L., Wasilenko W.J., Somers K.D.
Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines.
Oncogene 12:31-35(1996)

PubMed=9815580
Wu Y.-G., Palad A.J., Wasilenko W.J., Blackmore P.F., Pincus W.A., Schechter G.L., Spoonster J.R., Kohn E.C., Somers K.D.
Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole.
Clin. Cancer Res. 3:1915-1921(1997)

PubMed=11799138; DOI=10.1177/002215540205000207
Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.
Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection.
J. Histochem. Cytochem. 50:197-204(2002)

PubMed=17848307; DOI=10.1016/j.ijrobp.2007.04.082
Yarbrough W.G., Whigham A., Brown B., Roach M., Slebos R.J.C.
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas.
Int. J. Radiat. Oncol. Biol. Phys. 69:S98-S101(2007)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=21833476; DOI=10.3892/or.2011.1418
Ma J., Lu S.-M., Yu L., Tian J.-J., Li J.-F., Wang H.-B., Xu W.
FaDu cell characteristics induced by multidrug resistance.
Oncol. Rep. 26:1189-1195(2011)

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23613873; DOI=10.1371/journal.pone.0061555
Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A., Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.
DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
PLoS ONE 8:E61555-E61555(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008
Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M., Simons A.L.
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Mol. Oncol. 9:1371-1383(2015)

PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528
Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B., Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A., Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.
Defects in the Fanconi anemia pathway and chromatid cohesion in head and neck cancer.
Cancer Res. 75:3543-3553(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

CLPUB00484
Xu Z.-H., Sun W.-W., Hang J.-B., Gao B.-L., Hu J.-A.
RNA-seq identified a novel functional MET fusion in head and neck cancer 5-8F cell line.
Int. J. Clin. Exp. Pathol. 9:8308-8317(2016)

PubMed=26754630; DOI=10.1186/s13046-016-0284-4
Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S., Ito Y., Myers J.N., Oridate N.
JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma.
J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28476783; DOI=10.21873/anticanres.11555
Hagemann J., Jacobi C., Hahn M., Schmid V., Welz C., Schwenk-Zieger S., Stauber R.H., Baumeister P., Becker S.
Spheroid-based 3D cell cultures enable personalized therapy testing and drug discovery in head and neck cancer.
Anticancer Res. 37:2201-2210(2017)

PubMed=28844650; DOI=10.1016/j.anl.2017.07.011
Cho K.-J., Park E.-J., Kim M.-S., Joo Y.-H.
Characterization of FaDu-R, a radioresistant head and neck cancer cell line, and cancer stem cells.
Auris Nasus Larynx 45:566-573(2017)

PubMed=29156801; DOI=10.18632/oncotarget.21174
Kalu N.N., Mazumdar T., Peng S., Shen L., Sambandam V., Rao X., Xi Y., Li L., Qi Y., Gleber-Netto F.O., Patel A., Wang J., Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.
Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines.
Oncotarget 8:86369-86383(2017)

PubMed=30135316; DOI=10.1172/jci.insight.122204
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004
van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I., Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.
Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
Oral Oncol. 98:53-61(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=33802339; DOI=10.3390/cancers13051069
Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.
Genotyping and characterization of HPV status, hypoxia, and radiosensitivity in 22 head and neck cancer cell lines.
Cancers (Basel) 13:1069.1-1069.12(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)